Spexib 150mg Capsule

• Spexib 150mg Capsule is usually taken once a day as prescribed by the doctor.
• Ceritinib 150mg should be taken with meals to reduce stomach upset and improve absorption.
• Follow your doctor's advice strictly regarding the dosage and duration.
  
• Swallow the capsule as a whole with a glass of water. Do not crush, chew, or break the capsule.

• If you forget to take a dose of Spexib 150mg Capsule, consult your doctor.
• Take your missed dose as soon as you remember it, but don’t double up on doses under any circumstances.
• If it’s nearly time for the next dose when you discover that you’ve forgotten one, just wait until the next dose.
  

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

• Khozin, S., Blumenthal, G. M., Zhang, L., Tang, S., Brower, M., Fox, E., ... & Pazdur, R. (2015). FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase–positive non–small cell lung cancer. Clinical cancer research, 21(11), 2436-2439.
  
• https://www.cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadPrescribingInfo/9Ceritinib.pdf
  
• Dhillon, S., & Clark, M. (2014). Ceritinib: first global approval. Drugs, 74(11), 1285-1291.
  
• Kim, D. W., Mehra, R., Tan, D. S., Felip, E., Chow, L. Q., Camidge, D. R., ... & Shaw, A. T. (2016). Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. The lancet oncology, 17(4), 452-463.
  
• Cooper, M. R., Chim, H., Chan, H., & Durand, C. (2015). Ceritinib: a new tyrosine kinase inhibitor for non-small-cell lung cancer. Annals of Pharmacotherapy, 49(1), 107-112.
  
• Soria, J. C., Tan, D. S., Chiari, R., Wu, Y. L., Paz-Ares, L., Wolf, J., ... & de Castro, G. (2017). First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. The Lancet, 389(10072), 917-929.